As such, there is significant interest in refining the selectivity and potency of PARP-1 inhibitors such as NMS-P118, a selective compound that inhibits PARP-1 80-fold more potently than PARP-2 and totally represses the growth of breast cancer cells and pancreatic ductal adenocarcinoma xenografts [25]. This evidence concerns the gene PARP1 and pancreatic ductal adenocarcinoma.